Save 20% on All Global Market Reports With Code ONLINE20 – Gain Insights Into Tariffs, Inflation, and Industry Trends
What Is the Potential Market Growth Rate of the Celiac Disease Treatment Market?
The celiac disease treatment market size has grown strongly in recent years. It will grow from $0.61 billion in 2024 to $0.66 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to rise in prevalence of celiac disease, increase in awareness and diagnosis rates, growth in demand for non-dietary treatment options, strong pipeline of innovative therapies, supportive regulatory initiatives, and increase in investment from pharmaceutical companies.
The celiac disease treatment market size is expected to see strong growth in the next few years. It will grow to $0.94 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to rising global prevalence of celiac disease, increasing awareness and diagnosis rates, ongoing clinical trials for novel treatments, growing demand for gluten-free alternatives, supportive regulatory initiatives for orphan diseases, and rising healthcare expenditure. Major trends in the forecast period include adoption of novel non-dietary therapies, advancements in enzyme supplements, personalized medicine approaches, development of peptide-based immunotherapies, improved diagnostic tools, and advancements in clinical trials.
Claim your free report sample now:
What Are the Primary Growth Contributors in the Celiac Disease Treatment Market?
The rise in the prevalence of diabetes is expected to propel the growth of the celiac disease treatment market going forward. Diabetes is a chronic medical condition where the body is unable to regulate blood sugar or glucose levels properly. The increasing prevalence of diabetes is due to shared dietary management needs, as both diabetes and celiac disease require careful control of food intake to manage blood sugar levels and prevent complications. Celiac disease treatment aids diabetes by promoting a gluten-free diet, which can help improve overall digestive health and nutrient absorption. It supports better blood sugar control and reduces complications in individuals managing both conditions. For instance, in June 2024, according to the National Health Service, a UK-based government department, around 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the rise in the prevalence of diabetes is driving the growth of the celiac disease treatment market.
What Are the Major Product/Service Segments in the Celiac Disease Treatment Market?
The celiac disease treatment market covered in this report is segmented –
1) By Treatment Type: Vitamins And Minerals, Gluten Degrading Enzymes, Symptomatic Treatment, Other Treatments
2) By Enzyme Type: Distension, Diarrhoea, Anorexia, Bloating, Gas, Fatigue
3) By Diagnosis: Serological Tests, Genetic Testing, Biopsy
4) By Distribution Channel: Hospitals, Research Centres, Clinics, Other Distribution Channels
Subsegments:
1) By Vitamins and Minerals: Iron Supplements, Calcium Supplements, Vitamin D, Vitamin B12, Multivitamins
2) By Gluten Degrading Enzymes: Endopeptidases, Exopeptidases, Combination Enzyme Formulations
3) By Symptomatic Treatment: Antidiarrheal Medications, Antidepressants, Anti-inflammatory Drugs, Immunosuppressive Agents
4) By Other Treatments: Probiotics, Immunotherapy, Stem Cell Therapy, Experimental Therapies
What Are the Major Trends Impacting the Celiac Disease Treatment Market?
Major companies operating in the celiac disease treatment market are focusing on developing oral therapies, such as small molecule therapies, to provide targeted relief by blocking immune responses to gluten, improving patient adherence, and offering alternatives to strict gluten-free diets. Small molecule therapies are tiny drugs that enter cells easily to target and treat disease-causing proteins or enzymes. For instance, in February 2025, Immunic Inc., a US-based biotechnology company, launched IMU-856. IMU-856 is a small molecule that increases endogenous glucagon-like peptide-1 (GLP-1) levels, which helps improve intestinal barrier function in celiac disease patients. It also enhance nutrient absorption and alleviate symptoms without suppressing immune activity.
Who Are the Prominent Players in theCeliac Disease Treatment Market?
Major companies operating in the celiac disease treatment market are Pfizer Inc., Johnson And Johnson, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceuticals Company Ltd., Amgen Inc., General Mills Inc., Viatris Inc., Teva Pharmaceutical Inc., Nestlé Health Science, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Pharmaceuticals Inc., Glenmark Pharmaceuticals Company Ltd., West-Ward Pharmaceuticals Company Ltd, Innovate Biopharmaceutical, Acto Biosciences, ImmunogenX
Get the full celiac disease treatment market report here:
What Are the Opportunities and Challenges for Celiac Disease Treatment Market Across Regions?
North America was the largest region in the celiac disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the celiac disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment